Form 4: Recursion Pharma CFO Sells Shares Under 10b5-1 Plan

Recursion Pharmaceuticals' CFO, Ben R. Taylor, sold 21,383 shares of Class A Common Stock for $4.18 per share on December 29, 2025, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Ben R. Taylor, Chief Financial Officer of Recursion Pharmaceuticals, Inc. (RXRX), reported a sale of company stock.
• The transaction involved the disposition of 21,383 shares of Class A Common Stock.
• The shares were sold at a price of $4.18 per share.
• The sale occurred on December 29, 2025.
• Following this transaction, Mr. Taylor beneficially owns 761,550 shares of Class A Common Stock directly.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Taylor on September 30, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can be perceived negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns that the sale is based on new, negative non-public information. It is likely for personal financial planning.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance and not based on recent non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the insider's direct ownership in the company.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends. It is specific to the reporting person and Recursion Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders may interpret the insider sale as a slight negative signal, although the presence of a 10b5-1 plan typically reduces this concern as it indicates a pre-scheduled transaction for personal liquidity or diversification rather than a reaction to recent company performance.

Key Dates

Recommendation

A Form 4 filing detailing an insider sale, especially one executed under a Rule 10b5-1 plan, typically does not provide sufficient new information to warrant a change in investment recommendation. Such sales are often for personal financial planning and are pre-scheduled, thus not reflecting a change in the insider's view of the company's immediate prospects. Investors should consider the company's broader financial performance and strategic outlook rather than this single transaction.

Keywords

Recursion Pharmaceuticals, RXRX, Insider Trading, Form 4, Stock Sale, CFO, Ben R. Taylor, 10b5-1 Plan, Biotechnology, Pharmaceuticals